Detrimental effects of an inhaled phosphodiesterase-4 inhibitor on lung inflammation in ventilated preterm lambs exposed to chorioamnionitis are dose dependent

Hütten, Matthias C., Fehrholz, Markus, Konrad, Franziska M., Ophelders, Daan, Kleintjes, Clementine, Ottensmeier, Barbara, Spiller, Owen Brad ORCID: https://orcid.org/0000-0002-9117-6911, Glaser, Kirsten, Kramer, Boris W. and Kunzmann, Steffen 2019. Detrimental effects of an inhaled phosphodiesterase-4 inhibitor on lung inflammation in ventilated preterm lambs exposed to chorioamnionitis are dose dependent. Journal of Aerosol Medicine and Pulmonary Drug Delivery 32 (6) , pp. 396-404. 10.1089/jamp.2019.1528

Preview

PDF - Accepted Post-Print Version Download (811kB) | Preview

Abstract

Background: Treatment of bronchopulmonary dysplasia in preterm infants is challenging due to its multifactorial origin. In rodent models of neonatal lung injury, selective inhibition of phosphodiesterase 4 (PDE4) has been shown to exert anti-inflammatory properties in the lung. We hypothesized that GSK256066, a highly selective, inhalable PDE4 inhibitor, would have beneficial effects on lung injury and inflammation in a triple hit lamb model of Ureaplasma parvum (UP)-induced chorioamnionitis, prematurity, and mechanical ventilation. Methods: Twenty-one preterm lambs were surgically delivered preterm at 129 days after 7 days intrauterine exposure to UP. Sixteen animals were subsequently ventilated for 24 hours and received endotracheal surfactant and intravenous caffeine citrate. Ten animals were randomized to receive twice a high (10 μg/kg) or low dose (1 μg/kg) of nebulized PDE4 inhibitor. Results: Nebulization of high, but not low, doses of PDE4 inhibitor led to a significant decrease in pulmonary PDE activity, and was associated with lung injury and vasculitis, influx of neutrophils, and increased proinflammatory cytokine messenger RNA levels. Conclusion: Contrary to our hypothesis, we found in our model a dose-dependent proinflammatory effect of an inhaled highly selective PDE4 inhibitor in the lung. Our findings indicate the narrow therapeutic range of inhaled PDE4 inhibitors in the preterm population.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Mary Ann Liebert
ISSN:	1941-2711
Date of First Compliant Deposit:	24 October 2019
Date of Acceptance:	8 July 2019
Last Modified:	27 Nov 2024 19:30
URI:	https://orca.cardiff.ac.uk/id/eprint/126276

Citation Data

Cited 4 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item